Jasper Therapeutics, Inc. (JSPR )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol JSPR
- Company Jasper Therapeutics, Inc.
- Price $0.34
- Changes Percentage -22.99
- Change -0.1018
- Day Low $0.34
- Day High $0.45
- Year High $7.19
- Year Low $0.43
- Market Cap $8,651,243
- Price Avg 50 EMA (D) $0.9
- Price Avg 200 EMA (D) $1.68
- Exchange NASDAQ
- Volume 1,639,292
- Average Volume 490,401
- Open $0.44
- Previous Close $0.44
- EPS -2.58
- PE -0.21
- Earnings Announcement 2026-08-12 04:00:00
- Shares Outstanding $16,252,570
Company brief: JASPER THERAPEUTICS, INC. (JSPR )
- Healthcare
- Biotechnology
- Mr. Ronald A. Martell
- https://jaspertherapeutics.com
- US
- N/A
- 01-10-2020
- US4718712023
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.